First Medicare-Accepted Oral Appliance Treatment for All Severities of Obstructive Sleep Apnea in Adults
LITTLETON, Colo., April 9, 2024 -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities…
March 28, 2024 16:05 ET | Source: Vivos Therapeutics, Inc
Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea
Annual Operating Expenses Declined 27% Due to Success of Cost Cutting Initiatives
Management to Host Conference Call Today at 5:00 pm ET
LITTLETON,…
Call Scheduled for Today, Thursday, March 28, 2024 at 5:00 pm ET
March 28, 2024 07:30 ET | Source: Vivos Therapeutics, Inc
LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective…
February 15, 2024 08:00 ET| Source: Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea…
United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics' CPAP Devices Create Significant Revenue Opportunities for Vivos Devices
February 06, 2024 07:30 ET| Source: Vivos Therapeutics, Inc
LITTLETON, Colo., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and…
New Dentist Inquiries Jumped 600% and
Signed Dentist Enrollment Contracts up 38% Sequentially Over Q3
CARE Oral Medical Device Unit Orders Increased 26% Following FDA Clearance
LITTLETON, Colo., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly…
Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSA
December 11, 2023 07:30 ET | Source: Vivos Therapeutics, Inc
LITTLETON, Colo., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical…
With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos
LITTLETON, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and…
November 14, 2023 16:05 ET | Source: Vivos Therapeutics, Inc Follow
Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold
New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare, Expected to Add Potentially Significant New Revenue Opportunities
Management to Host Conference Call Today at 5:00…
Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement
October 24, 2023 07:30 ET | Source: Vivos Therapeutics, Inc Follow
LITTLETON, Colo., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS a leading medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate…